Mathias Schmidt
Director/Board Member at JCR PHARMACEUTICALS CO., LTD.
Mathias Schmidt active positions
| Companies | Position | Start | End |
|---|---|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Director/Board Member | 31/05/2020 | - |
| Corporate Officer/Principal | 31/05/2020 | - | |
ArmaGen, Inc.
 ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Director/Board Member | 30/09/2016 | - |
| Chief Executive Officer | - | - | |
| JCR USA, Inc. | Chief Executive Officer | - | - |
| President | - | - |
Career history of Mathias Schmidt
Training of Mathias Schmidt
| University of Freiburg | Doctorate Degree |
| Universität Stuttgart | Graduate Degree |
Statistics
International
| Germany | 3 |
| United States | 3 |
| Japan | 2 |
Operational
| Director/Board Member | 2 |
| Chief Executive Officer | 2 |
| Corporate Officer/Principal | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
| Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| JCR PHARMACEUTICALS CO., LTD. | Health Technology |
| Private companies | 2 |
|---|---|
ArmaGen, Inc.
ArmaGen, Inc. Hospital/Nursing ManagementHealth Services ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA. | Health Services |
| JCR USA, Inc. |
- Stock Market
- Insiders
- Mathias Schmidt
- Experience
